Jonathan Violin - Feb 2, 2023 Form 4/A - Amendment Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Chief Executive Officer, Director
Signature
/s/ Lara Meisner, Attorney-in-Fact for Jonathan Violin
Stock symbol
VRDN
Transactions as of
Feb 2, 2023
Transactions value $
-$1,832,500
Form type
4/A - Amendment
Date filed
2/7/2023, 05:35 PM
Date Of Original Report
Feb 7, 2023
Previous filing
Jun 21, 2022
Next filing
Jun 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Options Exercise $7.5K +50K +10.4% $0.15* 531K Feb 2, 2023 Direct F1
transaction VRDN Common Stock Sale -$1.84M -50K -9.42% $36.80 481K Feb 2, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -50K -17.29% $0.00 239K Feb 2, 2023 Common Stock 50K $0.15 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Jonathan Violin is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Due to a broker error, the Form 4 filed by the Reporting Person on February 3, 2023 incorrectly reported the source of shares sold on February 2, 2023 pursuant to the Reporting Person's Rule 10b5-1 trading plan. This amendment reflects the exercise of stock options for 50,000 shares of common stock, which were the source of the shares sold.
F2 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $36.1523 to $37.3689. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The option vested 25% on September 23, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.